We also found that aldometanib at such doses did not affect energy levels, as evidenced by the unchanged ratios of AMP:ATP or ADP:ATP in both HCC and adjacent noncancerous tissues (Supplementary information, Fig. S1c), consistent with a previous report that aldometanib acts to activate AMPK via the lysosomal pathway, independently of the increase in AMP.38 Here, PRKAA1 is linked to hepatocellular carcinoma.